News
-
-
COMMUNIQUÉ DE PRESSE
Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama®
Formycon receives EU approval for biosimilar FYB203 (aflibercept) to Eylea®, brands AHZANTIVE® and Baiama® for nAMD and retinal diseases. Teva to market AHZANTIVE® in Europe -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel
Teva partners with Formycon for commercialization of biosimilar FYB203 (Eylea®) in Europe and Israel, aiming to expand access to innovative medicines -
-
